|
Name |
(12Z)-9,10-Dihydroxyoctadec-12-enoate
|
| Molecular Formula | C18H34O4 | |
| IUPAC Name* |
(Z,9R,10R)-9,10-dihydroxyoctadec-12-enoic acid
|
|
| SMILES |
CCCCC/C=C\C[C@H]([C@@H](CCCCCCCC(=O)O)O)O
|
|
| InChI |
InChI=1S/C18H34O4/c1-2-3-4-5-7-10-13-16(19)17(20)14-11-8-6-9-12-15-18(21)22/h7,10,16-17,19-20H,2-6,8-9,11-15H2,1H3,(H,21,22)/b10-7-/t16-,17-/m1/s1
|
|
| InChIKey |
XEBKSQSGNGRGDW-GJWDQICYSA-N
|
|
| Synonyms |
(+/-)-Threo-9,10-dihydroxy-12(Z)-octadecenoic acid; 263399-34-4; 9,10-DiHOME; 9,10-hydroxyoctadec-12(Z)-enoic acid; (12Z)-9,10-Dihydroxyoctadec-12-enoate; DTXSID701346557; 9,10-dihydroxy-12Z-octadecenoate; 9,10-hydroxyoctadec-12(Z)-enoate; ZINC12496444; threo-9,10-Dihydroxy-12(Z)-octadecenoic acid; (9R,10R,12Z)-9,10-Dihydroxy-12-octadecenoic acid; (9R,10R,12Z)-9,10-DIHYDROXYOCTADEC-12-ENOIC ACID
|
|
| CAS | 263399-34-4 | |
| PubChem CID | 25320862 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 314.5 | ALogp: | 4.6 |
| HBD: | 3 | HBA: | 4 |
| Rotatable Bonds: | 15 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 77.8 | Aromatic Rings: | 0 |
| Heavy Atoms: | 22 | QED Weighted: | 0.303 |
| Caco-2 Permeability: | -5.258 | MDCK Permeability: | 0.00005110 |
| Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.033 |
| Human Intestinal Absorption (HIA): | 0.175 | 20% Bioavailability (F20%): | 0.999 |
| 30% Bioavailability (F30%): | 0.999 |
| Blood-Brain-Barrier Penetration (BBB): | 0.475 | Plasma Protein Binding (PPB): | 96.44% |
| Volume Distribution (VD): | 0.542 | Fu: | 1.30% |
| CYP1A2-inhibitor: | 0.072 | CYP1A2-substrate: | 0.187 |
| CYP2C19-inhibitor: | 0.02 | CYP2C19-substrate: | 0.109 |
| CYP2C9-inhibitor: | 0.047 | CYP2C9-substrate: | 0.988 |
| CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.205 |
| CYP3A4-inhibitor: | 0.011 | CYP3A4-substrate: | 0.017 |
| Clearance (CL): | 3.955 | Half-life (T1/2): | 0.916 |
| hERG Blockers: | 0.07 | Human Hepatotoxicity (H-HT): | 0.084 |
| Drug-inuced Liver Injury (DILI): | 0.013 | AMES Toxicity: | 0.016 |
| Rat Oral Acute Toxicity: | 0.014 | Maximum Recommended Daily Dose: | 0.037 |
| Skin Sensitization: | 0.876 | Carcinogencity: | 0.067 |
| Eye Corrosion: | 0.095 | Eye Irritation: | 0.819 |
| Respiratory Toxicity: | 0.255 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001099 | ![]() |
0.672 | D0O1PH | ![]() |
0.568 | ||
| ENC001589 | ![]() |
0.672 | D0O1TC | ![]() |
0.531 | ||
| ENC001613 | ![]() |
0.667 | D09SRR | ![]() |
0.462 | ||
| ENC001554 | ![]() |
0.631 | D0I4DQ | ![]() |
0.461 | ||
| ENC001535 | ![]() |
0.616 | D0UE9X | ![]() |
0.457 | ||
| ENC001100 | ![]() |
0.616 | D0Z5BC | ![]() |
0.448 | ||
| ENC001555 | ![]() |
0.616 | D0XN8C | ![]() |
0.446 | ||
| ENC001419 | ![]() |
0.616 | D06FEA | ![]() |
0.413 | ||
| ENC001584 | ![]() |
0.616 | D0OR6A | ![]() |
0.406 | ||
| ENC001591 | ![]() |
0.616 | D04RGA | ![]() |
0.376 | ||